Assembly Biosciences (ASMB) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View ASMB analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1-year target prices for Assembly Biosciences' stock. Their ASMB share price forecasts range from $1.50 to $3.00. On average, they anticipate the company's stock price to reach $2.17 in the next twelve months. This suggests a possible upside of 125.7% from the stock's current price.
View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts.

Assembly Biosciences' stock was trading at $1.30 at the beginning of the year. Since then, ASMB stock has decreased by 26.2% and is now trading at $0.96.
View the best growth stocks for 2023 here.

Assembly Biosciences saw a decline in short interest in May. As of May 15th, there was short interest totaling 161,300 shares, a decline of 5.5% from the April 30th total of 170,600 shares. Based on an average trading volume of 214,900 shares, the short-interest ratio is presently 0.8 days.
View Assembly Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ASMB earnings forecast.

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings results on Wednesday, March, 22nd. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.10.

ETFMG Treatments Testing and Advancements ETF holds 16,315 shares of ASMB stock, representing 0.07% of its portfolio.

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC).

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Assembly Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.08%), Hudson Bay Capital Management LP (1.82%), Platinum Investment Management Ltd. (1.71%), Renaissance Technologies LLC (1.47%), Federated Hermes Inc. (0.70%) and Dimensional Fund Advisors LP (0.55%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Timothy A Springer, William E Iv Delaney and William E Iv Delaney.
View institutional ownership trends.

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASMB stock can currently be purchased for approximately $0.96.

Assembly Biosciences (NASDAQ:ASMB) has a market capitalization of $50.04 million and generates $6.25 million in revenue each year. The biopharmaceutical company earns $-93,090,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

The company employs 102 workers across the globe.

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.assemblybio.com. The biopharmaceutical company can be reached via phone at (833) 509-4583, via email at lglaser@assemblybio.com, or via fax at 646-706-5101.